|
|
More Articles...
- Liver Forum 16
- Liver Forum 15
- Liver Forum 14
- Liver Forum 13
- Liver Forum 12
- Histology Series 4: Improving The Reliability of NASH Clinical Trial Outcomes: What Is the Optimal Number of Hepatopathologists and Digital Slides, Pros and Cons
- Regulatory Guidance on NASH Data Specifications in Clinical Trials
- Histology Series Session 5: Causality Assessment and the Role of Liver Biopsy as Part of the Evaluation of Suspected DILI in NASH Clinical Trials
- Histology Series Session 3: The Role of Liver Biopsy as part of Causality Assessment for Suspected DILI in NASH Clinical Trials
- Histology Series Session 2: Innovations: Utilizing Digital Methods and New Technology
- Histology Series Session 1: Increasing the Reliability of Histology in NASH Clinical Trials
- Liver Forum 11 - 2020 NASH Updates Webinar
- PSC Forum 3 and Liver Forum 10
- Liver Forum 8
- Liver Forum 7
- Liver Forum 6
- Liver Forum 1
- Liver Forum 2
- Liver Forum 3
- Liver Forum 4
- Liver Forum 5
